Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New pacemaker design aims for safer heart pacing

NCT ID NCT06056817

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 02, 2026 · Updated 3 times

Summary

This early study tests a new pacemaker system in 10 adults who need a single-chamber pacemaker for a slow heart rate. The device is placed under the breastbone using a special tool, with electrodes touching the heart's outer lining. Researchers will check if the implant is safe and works well over 3 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Calyan pacemaker device
What this could lead to
If successful, this could offer a new, less invasive pacemaker option for people with slow heart rates.
What could go wrong
This is a very early feasibility study with only 10 people, so results may not apply broadly. The device is new and risks like infection or device failure are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 or above 2. Willing and capable of providing informed consent 3. Class I or IIa indication for implantation of a single-chamber ventricular pacemaker, according to ACC/AHA/HRS guidelines 4. A life expectancy of at least one year, and is a suitable candidate based on overall health and well-being Exclusion Criteria: 1. Patients with complete AV block or other pacemaker-dependent conditions 2. Patients in whom a substernal device implant should be avoided: 1. Any prior sternotomy; 2. Any prior medical condition or procedure that leads to adhesions in the anterior mediastinal space; 3. Any marked sternal abnormality, such as pectus excavatum or pectus carinatum 4. Prior abdominal surgery in the epigastric region 5. Planned sternotomy 6. Prior or planned chest radiotherapy 7. Hiatal hernia that distorts mediastinal anatomy 8. Adhesions in the anterior mediastinal space 9. Severe obesity so that subxiphoid/substernal tunneling cannot be safely performed 3. Patients with severe RV dilation, gross hepatosplenomegaly, or severe obesity such that subxiphoidal/substernal tunneling cannot be safely performed 4. Patients with a class III indication for a permanent pacemaker 5. Patients with decompensated heart failure not due to bradycardia and expected to worsen with chronic RV pacing 6. Patients with an implanted cardiac pacemaker, cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device, or planned implantation of a cardioverter defibrillator, cardiac resynchronization device, or neurostimulator device 7. Patients with a current or planned implantation of a substernal device, or any implanted device that would interfere with the implantation or operation of a substernal device 8. Patients who have previously undergone an open-heart surgical procedure. 9. Patients with an active infection 10. Patient on chronic oral anticoagulation which cannot be temporarily discontinued for surgery 11. Patients with a condition in which pericardial pacing would be difficult or impossible, such as acute pericarditis, chronic pericardial effusion or pericardial thickening or calcification, cardiac tamponade, or chronic restrictive pericarditis 12. Patients who have tested positive for the COVID-19 in the past 3 months, or are currently showing symptoms consistent with COVID-19 13. Women of childbearing potential who are or might be pregnant at the time of the study or breastfeeding 14. Subjects with a life expectancy of less than 12 months 15. Patients who are currently enrolled or planning to participate in any concurrent clinical study with an investigational therapy 16. Patients with decompensated heart failure expected to worsen with chronic RV pacing 17. Patients with COPD with oxygen dependence

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bradycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Bradycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.